Neratinib Improved 5-Year DFS in HER2-Positive Breast Cancer

Article

A 5-year follow-up analysis showed that 1 year of extended adjuvant therapy with neratinib, given after chemotherapy and trastuzumab, can significantly improve rates of clinically relevant relapses in women with HER2-positive breast cancer.

A 5-year follow-up analysis showed that 1 year of extended adjuvant therapy with neratinib, given after chemotherapy and trastuzumab, can significantly improve rates of clinically relevant relapses in women with HER2-positive breast cancer.

“Despite the proven benefits of trastuzumab in the adjuvant setting, data from long-term follow-up show that 15% to 24% of patients’ breast cancers recur after a median of 8–11 years,” wrote study authors led by Miguel Martin, MD, PhD, of Universidad Complutense in Madrid. The ExteNET trial previously found that neratinib, a pan-HER tyrosine kinase inhibitor, can improve invasive disease-free survival (DFS) at a 2-year follow-up; results that led to US Food and Drug Administration approval of neratinib as extended adjuvant treatment in early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. The new analysis extends that follow-up period to 5 years.

The randomized, double-blind, phase III trial included 2,840 women with early HER2-positive breast cancer, divided evenly between a neratinib group and a placebo group. The study was conducted in 40 countries, and the median follow-up for the new analysis was 5.2 years; results were published online ahead of print in Lancet Oncology.

There were 116 invasive disease-free survival events in the neratinib group, compared with 163 such events in the placebo group, for a hazard ratio of 0.73 (95% CI, 0.57–0.92; P = .0083). The 5-year invasive DFS rate was 90.2% with the study drug and 87.7% without it.

There were also reductions in distant recurrence and local or regional recurrences with neratinib. There were 91 distant recurrences with neratinib (6.4%) compared with 111 with placebo (7.8%), and 12 local or regional recurrences with the study drug (0.8%) compared with 35 with placebo (2.5%). Overall survival data was not yet mature, with a total of 121 deaths in the study due to disease progression (102 patients) or other reasons (19 patients).

The primary safety analysis was reported at the 2-year follow-up; the most common adverse events with neratinib included diarrhea, vomiting, and nausea. The authors noted that the extended analysis yielded no suggestion of increased long-term toxicity, in particular with regard to cardiac toxicity or secondary malignancies.

“The 5-year analysis showed that the superior efficacy of neratinib, compared with placebo, was maintained every year after randomization, with a significant reduction in the risk of an invasive DFS event after 5 years of follow-up,” the authors concluded, adding that subgroup analyses suggest a greater benefit in patients with hormone receptor–positive disease. The overall survival analysis will be conducted after 248 deaths have occurred.

Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Related Content